In our in silico analysis, we recently showed that, apart from repressing MYC, ras, and HMGA2, let-7 may also target CYP19A1, ESR1, and ESR2, thereby potentially blocking estrogen signalling in er-positive breast cancers. Here, ESR2 is linked to breast carcinoma.